Enzo Biochem Company Profile (NYSE:ENZ)

About Enzo Biochem

Enzo Biochem logoEnzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: ENZ
  • CUSIP:
Key Metrics:
  • Previous Close: $6.66
  • 50 Day Moving Average: $6.78
  • 200 Day Moving Average: $6.29
  • 52-Week Range: $46,289,000.00 - $4.00
  • Trailing P/E Ratio: 7.92
  • Foreward P/E Ratio: -37.00
  • P/E Growth: 0.00
  • Market Cap: $308.28M
  • Outstanding Shares: 46,289,000
  • Beta: 1.4
Profitability:
  • Net Margins: 37.91%
  • Return on Equity: -12.25%
  • Return on Assets: -9.21%
Debt:
  • Current Ratio: 4.35%
  • Quick Ratio: 4.01%
Additional Links:
Companies Related to Enzo Biochem:

Analyst Ratings

Consensus Ratings for Enzo Biochem (NYSE:ENZ) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Enzo Biochem (NYSE:ENZ)
Show:
DateFirmActionRatingPrice TargetDetails
2/9/2016Dawson JamesReiterated RatingBuyView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Enzo Biochem (NYSE:ENZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
12/8/2016Q117($0.05)($0.03)$26.30 millionViewN/AView Earnings Details
10/13/2016Q416($0.06)($0.04)$26.60 millionViewN/AView Earnings Details
6/8/2016Q316($0.06)($0.04)$24.50 million$18.16 millionViewN/AView Earnings Details
3/9/2016Q216($0.06)($0.07)$24.43 million$24.60 millionViewN/AView Earnings Details
12/7/2015Q116($0.05)($0.05)$25.20 millionViewN/AView Earnings Details
10/13/2015Q415($0.06)($0.06)$24.60 million$25.70 millionViewListenView Earnings Details
6/9/2015Q315($0.06)($0.07)$24.40 millionViewN/AView Earnings Details
3/12/2015Q215($0.09)($0.09)$23.10 millionViewN/AView Earnings Details
12/9/2014Q114($0.08)($0.08)$24.50 millionViewListenView Earnings Details
10/9/2014($0.07)($0.06)ViewListenView Earnings Details
6/9/2014Q314($0.09)($0.01)$22.80 million$24.00 millionViewN/AView Earnings Details
3/11/2014Q2($0.08)($0.09)$22.00 million$22.93 millionViewListenView Earnings Details
12/11/2013Q1($0.06)($0.07)ViewListenView Earnings Details
10/16/2013Q413($0.08)$22.00 million$23.30 millionViewListenView Earnings Details
6/10/2013Q3 2013($0.15)$22.20 million$22.60 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enzo Biochem (NYSE:ENZ)
Current Year EPS Consensus Estimate: $-0.16 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.06)($0.06)($0.06)
Q3 20161($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Enzo Biochem (NYSE:ENZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enzo Biochem (NYSE:ENZ)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Enzo Biochem (NYSE:ENZ)
DateHeadline
News IconUveitis Treatment Market is Anticipated to Register at a Healthy CAGR of 7.3% by 2020 (NYSE:ENZ)
www.medgadget.com - February 24 at 11:34 AM
News IconNucleic Acid Labeling Market worth 1,925.7 Million USD by 2020. (NYSE:ENZ)
www.emailwire.com - February 23 at 5:00 PM
News IconNucleic acid labeling market worth 1,925.7 million USD by 2020 according to new research report (NYSE:ENZ)
www.whatech.com - February 23 at 3:19 AM
News IconNucleic Acid Labeling Market worth 1,925.7 Million USD by 2020 (NYSE:ENZ)
www.emailwire.com - February 22 at 5:16 PM
openpr.com logoGlobal Central Nervous System (CNS) Biomarkers Market: Trends and Opportunities 2024 (NYSE:ENZ)
www.openpr.com - February 22 at 5:16 PM
sbwire.com logoNonalcoholic Steatohepatitis Market Expected to Register High Revenue Growth Through 2024 (NYSE:ENZ)
www.sbwire.com - February 22 at 5:16 PM
News IconInvesting Focus: Indicators in View on Shares of Enzo Biochem Inc (ENZ) - Davidson Register (NYSE:ENZ)
davidsonregister.com - February 22 at 7:56 AM
News IconBiomarkers Market Worth 53.34 Billion USD by 2021 (NYSE:ENZ)
www.prnewswire.co.in - February 17 at 5:50 PM
News IconCentral Nervous System (CNS) Biomarkers Market Future Outlook by 2024 (NYSE:ENZ)
www.medgadget.com - February 14 at 5:55 PM
sbwire.com logoCentral Nervous System (CNS) Biomarkers Market: Developments Has Led to Increased Investment from Government & Private Players Is Fueling Market (NYSE:ENZ)
www.sbwire.com - February 11 at 3:34 AM
us.rd.yahoo.com logoGlaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View (NYSE:ENZ)
us.rd.yahoo.com - February 9 at 5:35 PM
sbwire.com logoSalmonella Testing Market Headed for Growth and Global Expansion by 2021 – PMR Report (NYSE:ENZ)
www.sbwire.com - February 9 at 3:33 AM
openpr.com logoRise in Heart Related Diseases is the Favorable Factor for the Central Nervous System (CNS) Biomarkers Market (NYSE:ENZ)
www.openpr.com - February 8 at 5:30 PM
finance.yahoo.com logoAmgen's Secondary Hyperparathyroidism Drug Approved in U.S. (NYSE:ENZ)
finance.yahoo.com - February 8 at 5:30 PM
finance.yahoo.com logoGW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1 (NYSE:ENZ)
finance.yahoo.com - February 8 at 5:30 PM
sbwire.com logoGlobal Uveitis Treatment Market to Spread a Predictable Worth of US $822.5 Million by 2020 (NYSE:ENZ)
www.sbwire.com - February 7 at 6:09 PM
finance.yahoo.com logoMallinckrodt (MNK) Tops on Earnings in Transition Quarter (NYSE:ENZ)
finance.yahoo.com - February 7 at 6:09 PM
us.rd.yahoo.com logoAstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales (NYSE:ENZ)
us.rd.yahoo.com - February 3 at 5:23 PM
News IconCentral Nervous System (CNS) Biomarkers Market: Advanced Technologies, Growth and Opportunities in Global Industry by 2024 (NYSE:ENZ)
www.medgadget.com - February 2 at 5:28 PM
zacks.com logoSeres Therapeutics (MCRB) Rises: Stock Adds 5% in Session (NYSE:ENZ)
www.zacks.com - February 1 at 5:33 PM
nasdaq.com logoEndo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval - Nasdaq (NYSE:ENZ)
www.nasdaq.com - February 1 at 3:42 AM
News IconMultimillion pound type 2 diabetes research centre coming to UK (NYSE:ENZ)
emfizz.com - January 31 at 5:41 PM
sbwire.com logoUveitis Treatment Market Is Expected to Register Highest CAGR of 7.3% During the Forecast Period by 2020 (NYSE:ENZ)
www.sbwire.com - January 31 at 5:41 PM
News IconGlobal Analysis for Nucleic Acid Labeling Market Volume By Region 2024 (NYSE:ENZ)
www.military-technologies.net - January 31 at 5:41 PM
zacks.com logoEndo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval (NYSE:ENZ)
www.zacks.com - January 31 at 5:41 PM
News IconCardiac Marker Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024 (NYSE:ENZ)
www.mynewsdesk.com - January 31 at 1:44 AM
News IconNucleic Acid Labeling Market Global Industry Volume and Region Analysis 2024 (NYSE:ENZ)
reports.pr-inside.com - January 31 at 1:44 AM
News IconDanish drugs giant invests in new United Kingdom university research centre (NYSE:ENZ)
rawgistafrica.com - January 31 at 1:44 AM
News IconMarket Check: Narrowing in on Shares of Enzo Biochem, Inc. (NYSE:ENZ) - The Tribune (NYSE:ENZ)
lakecitytribune.com - January 30 at 3:40 PM
News IconCCI, ADX, and Williams %R Review for Enzo Biochem Inc. (ENZ) - Rives Journal (NYSE:ENZ)
rivesjournal.com - January 30 at 12:20 PM
News IconStock Review: Checking in on Share of Enzo Biochem, Inc. (NYSE:ENZ) - Gilbert Daily (NYSE:ENZ)
gilbertdaily.com - January 30 at 12:20 PM
News IconFree Cash Flow Score in Focus for Enzo Biochem, Inc. (NYSE:ENZ) - The Tribune (NYSE:ENZ)
lakecitytribune.com - January 28 at 4:43 AM
nasdaq.com logoAstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA - Nasdaq (NYSE:ENZ)
www.nasdaq.com - January 27 at 6:39 PM
News IconWhat Are the Technicals Saying About These Shares: Enzo Biochem Inc. (ENZ) - Sherwood Daily (NYSE:ENZ)
sherwooddaily.com - January 27 at 6:39 PM
newsmaker.com.au logoNonalcoholic Steatohepatitis Market is Expected to Experience Immense Growth During 2015 - 2021 (NYSE:ENZ)
www.newsmaker.com.au - January 27 at 4:44 AM
News IconLearn details of the global central nervous system (cns) biomarkers market (NYSE:ENZ)
www.whatech.com - January 26 at 6:20 PM
News IconCardiac Marker Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024 (NYSE:ENZ)
www.medgadget.com - January 25 at 6:18 PM
finance.yahoo.com logoPerrigo's (PRGO) Generic Version of Topicort Okayed by FDA (NYSE:ENZ)
finance.yahoo.com - January 25 at 6:18 PM
finance.yahoo.com logoRoche (RHHBY) Arthritis Drug Actemra sBLA Accepted by FDA (NYSE:ENZ)
finance.yahoo.com - January 25 at 6:18 PM
openpr.com logoNonalcoholic Steatohepatitis Market - Asia Pacific Industry Analysis 2020 (NYSE:ENZ)
www.openpr.com - January 24 at 3:23 AM
us.rd.yahoo.com logoSynergy (SGYP) Trulance Wins FDA Approval for Constipation (NYSE:ENZ)
us.rd.yahoo.com - January 20 at 6:16 PM
nasdaq.com logoMallinckrodt to Pay $100M Fine to FTC for Questcor Matter - Nasdaq (NYSE:ENZ)
www.nasdaq.com - January 20 at 4:29 AM
News IconInvestor Probe: Watching Technicals for Enzo Biochem Inc. (ENZ) - Sherwood Daily (NYSE:ENZ)
sherwooddaily.com - January 20 at 4:29 AM
zacks.com logoMallinckrodt to Pay $100M Fine to FTC for Questcor Matter (NYSE:ENZ)
www.zacks.com - January 19 at 6:27 PM
capitalcube.com logoEnzo Biochem, Inc. – Value Analysis (NYSE:ENZ) : January 19, 2017 (NYSE:ENZ)
www.capitalcube.com - January 19 at 6:27 PM
finance.yahoo.com logoAllergan's Uterine Fibroids Candidate Positive in Phase III - Yahoo Finance (NYSE:ENZ)
finance.yahoo.com - January 19 at 3:25 AM
News IconChart Inspection on Shares of Enzo Biochem Inc. (ENZ) - Rives Journal (NYSE:ENZ)
rivesjournal.com - January 19 at 3:25 AM
News IconCentral Nervous System (CNS) Biomarkers Market (NYSE:ENZ)
reports.pr-inside.com - January 18 at 5:22 PM
News IconSolid growth ahead for Global Salmonella Testing Market by 2021 (NYSE:ENZ)
www.medgadget.com - January 18 at 5:22 PM
capitalcube.com logoEnzo Biochem, Inc. breached its 50 day moving average in a Bearish Manner : ENZ-US : January 18, 2017 (NYSE:ENZ)
www.capitalcube.com - January 18 at 5:22 PM

Social

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

When will Enzo Biochem announce their earnings?

Enzo Biochem is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

Who owns Enzo Biochem stock?

Enzo Biochem's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Evermore Global Advisors LLC (7.16%), Renaissance Technologies LLC (4.25%), Dimensional Fund Advisors LP (4.08%), First Light Asset Management LLC (2.18%), State Street Corp (1.23%) and Arrowstreet Capital Limited Partnership (0.87%).

Who sold Enzo Biochem stock? Who is selling Enzo Biochem stock?

Enzo Biochem's stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, First Light Asset Management LLC, Kopp Investment Advisors LLC, O Shaughnessy Asset Management LLC, Dimensional Fund Advisors LP and Metropolitan Life Insurance Co. NY.

Who bought Enzo Biochem stock? Who is buying Enzo Biochem stock?

Enzo Biochem's stock was bought by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Arrowstreet Capital Limited Partnership, Putnam Investments LLC, Russell Investments Group Ltd., GSA Capital Partners LLP, Perceptive Advisors LLC, Oxford Asset Management and State Street Corp.

How do I buy Enzo Biochem stock?

Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Enzo Biochem stock cost?

One share of Enzo Biochem stock can currently be purchased for approximately $6.66.

Enzo Biochem (NYSE:ENZ) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Earnings History Chart

Earnings by Quarter for Enzo Biochem (NYSE:ENZ)

Dividend History Chart

Dividend Payments by Quarter for Enzo Biochem (NYSE:ENZ)

Last Updated on 2/27/2017 by MarketBeat.com Staff